Project Grant R01HL166740
Award Date 9/1/25
Completion Date 8/31/27
Dollars Obligated $587K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
New Mexico, USA
Similar Awards
- This Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) provides $773,868 to Baylor College of Medicine to elucidate the mechanisms regulating inflammation and the role of regulatory T cells (Tregs) in the development of bronchopulmonary dysplasia-associated pulmonary hypertension (BPD-PH). The award aims to use well-established murine models and human biosamples to examine the mechanistic and therapeutic potential of Tregs in...
- This federal Project Grant award of $596,809.00 was provided by the National Heart Lung and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) to Emory University to support research on the role of the mitochondrial protein MitoNEET in pulmonary hypertension (PH). The project aims to define how MitoNEET regulates pulmonary artery smooth muscle cell mitochondrial function and proliferation, with the goal of identifying novel therapeutic targets and treatments for PH secondary to...
- This federal Project Grant award of $522,794.00 was provided by the National Heart Lung and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), to the University of Illinois for a project titled "HV1 IN PULMONARY HYPERTENSION". The project aims to examine the role of the voltage-gated proton channel HV1 in the development and progression of pulmonary hypertension, a serious cardiovascular condition. The research will apply transgenic mouse...
- The National Heart, Lung, and Blood Institute (NHLBI), via the Cardiovascular Diseases Research program (CFDA 93.837), awarded a $564,445 Project Grant to the University of Texas Health Science Center at Houston (UTHealth) to fund research on "Targeting Hypoxia-Inducible Factors (HIFs) for Heart and Lung Disease." The 6-year grant, starting on March 1, 2025 and ending on December 31, 2031, supports three complementary research projects focused on investigating the upstream regulation...
- This Project Grant award of $143,819 from the National Heart, Lung, and Blood Institute's Cardiovascular Diseases Research program (CFDA 93.837) supports research to investigate the role of the mitochondrial acid-sensing ion channel 1 (ASIC1A) in pulmonary hypertension. The project aims to define the mechanisms of ASIC1A trafficking and its impact on pulmonary arterial smooth muscle cell function, with the goal of identifying novel molecular targets to improve treatment for pulmonary...
- The University of New Mexico was awarded a $522,990 Project Grant under the National Institutes of Health (NIH) National Heart, Lung, and Blood Institute's Cardiovascular Diseases Research program (CFDA 93.837). The grant, awarded on September 1, 2025, will support research to elucidate the mechanisms underlying the counter-regulation of allergic airway inflammation by regulating the responsiveness of Group 2 Innate Lymphoid Cells (ILC2s). The proposed studies aim to address the knowledge gap in...
- This federal Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) provides $1,385,536 to Rhode Island Hospital to conduct research on pulmonary arterial hypertension (PAH). The goal is to characterize endothelial cell (EC) dysfunction in PAH, with a focus on understanding the role of anoikis resistance - abnormal programmed cell death triggered by cell detachment from the vessel wall. The research will leverage a "cell...
- This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) provides $658,885 to the University of Missouri System to investigate the role of the protein Response Gene to Complement 32 (RGC-32) in regulating endothelial-mesenchymal transition (EndoMT) and the development of pulmonary arterial hypertension (PAH). The research aims to determine the molecular mechanisms by which RGC-32 regulates EndoMT in...
- This Project Grant award from the National Heart, Lung, and Blood Institute (CFDA Program 93.837 Cardiovascular Diseases Research) provides $730,070 to the University of Arizona to develop and test a novel class of hybrid polyplex nanoparticles (P22-F1 PBAE/PEI/PEG) that can specifically target and deliver DNA plasmids to lung capillary endothelial cells. The goal is to stimulate lung regeneration and decrease pulmonary hypertension in mouse and rat models of bronchopulmonary dysplasia, a severe...
- This Project Grant award for $1,063,324 from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) supports research on CD4+ T cell immunity in the respiratory tract, with a focus on understanding the mechanisms underlying host defense against extracellular pathogens, particularly in the area of Type 17 cytokines and tissue resident memory CD4+ T cells. The research will utilize murine and primate respiratory tract samples to assess the metabolic...